Shandong Boan Biotechnology Co., Ltd. (BOAN BIOTECH) disclosed a repurchase of 500,000 H shares on 10 September 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The buyback, executed on-market, was completed at prices ranging from HKD 2.70 to HKD 2.82 per share, for a volume-weighted average cost of HKD 2.76 and an aggregate outlay of HKD 1.38 million. All repurchased shares are being held as treasury stock.

Key share capital movements after the transaction are as follows: • Issued shares outstanding (excluding treasury shares) fell 0.08 % to 614.43 million. • Treasury shares increased to 7.90 million from 7.40 million. • Total issued shares remained unchanged at 622.33 million, as the repurchased shares have not been cancelled.

The repurchase was conducted under the mandate approved by shareholders on 22 June 2026, which authorizes the company to buy back up to 62.23 million shares. Cumulative purchases under this mandate now stand at 7.90 million shares, representing 1.27 % of the issued share base on the mandate date.

In line with Hong Kong listing rules, BOAN BIOTECH is subject to a moratorium on issuing new shares or disposing of treasury shares until 10 October 2026.